Prognostic significance of tumor deposit counts in stage III colorectal cancer based on T/N staging and chemotherapy status: A retrospective cohort study.

Chenxiao Zheng, Lingsha Xu, Binbin Ou, Ibrahim Mohamed Bakour Abdourahaman, Xuanqin Chen, Hangjia Xu, Yating Zheng, Yifei Pan
Author Information
  1. Chenxiao Zheng: The First Affiliated Hospital of Wenzhou Medical University, PR China.
  2. Lingsha Xu: The First Affiliated Hospital of Wenzhou Medical University, PR China.
  3. Binbin Ou: Gongshu District Integrated Traditional Chinese and Western Medicine Hospital in Hangzhou, PR China.
  4. Ibrahim Mohamed Bakour Abdourahaman: The First Affiliated Hospital of Wenzhou Medical University, PR China.
  5. Xuanqin Chen: The First Affiliated Hospital of Wenzhou Medical University, PR China.
  6. Hangjia Xu: The First Affiliated Hospital of Wenzhou Medical University, PR China.
  7. Yating Zheng: The First Affiliated Hospital of Wenzhou Medical University, PR China.
  8. Yifei Pan: The First Affiliated Hospital of Wenzhou Medical University, Department of Colorectal Anal Surgery, PR China.

Abstract

Background: We aimed to evaluate the impact of tumor deposit (TD) count on cancer-specific survival (CSS) and disease-free survival (DFS) in stage III colorectal cancer (CRC) patients stratified by T and N staging, and further explore its impact on chemotherapy effect.
Method: We determined the optimal TD cut-off value for stage III CRC patients from the SEER database utilizing X-tile analysis, and retrospectively analyzed the clinicopathological data of 443 patients from the First Affiliated Hospital of Wenzhou Medical University from 2019 to 2020. Chi-square (χ2) tests compared categorical variables. Kaplan-Meier assessed CSS and DFS. Cox regression model evaluated prognostic factors on CSS and DFS.
Results: 2TD is the optimal cutoff value for prognosis in Stage III CRC, in the low-risk group (T1-T3 and N1), ≥3TD patients faced higher cancer-specific mortality (HR = 3.445, 95%CI = 1.254-9.465, P = 0.017) and recurrence risks (HR = 1.934, 95%CI = 1.095-3.416, P = 0.024) vs. 1-2TD, while 1-2TD and no-TD patients showed no difference in survival. In the high-risk group (T4 or N2), both ≥3TD and 1-2TD patients had poor prognosis. Chemotherapy reduced cancer-specific mortality in both groups (1-2TD: HR = 0.347, 95%CI = 0.138-0.870, P = 0.024; ≥3TD: HR = 0.272, 95%CI = 0.077-0.960, P = 0.043) but did not significantly improve recurrence risk (1-2TD: P = 0.177; ≥3TD: P = 0.058).
Conclusion: TD indicates poor prognosis in stage III CRC, with ≥3 TD significantly worsening survival, yet the prognosis remains poor in TD-positive patients with high-risk (T4 or N2) regardless of TD count. Moreover, TD count does not influence chemotherapy's mortality benefit.

Keywords

References

  1. Int J Surg. 2018 Aug;56:188-194 [PMID: 29936197]
  2. Dis Colon Rectum. 2014 Apr;57(4):467-74 [PMID: 24608303]
  3. J Clin Oncol. 2017 Apr 1;35(10):1119-1127 [PMID: 28029327]
  4. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  5. Chin J Cancer Res. 2023 Jun 30;35(3):233-238 [PMID: 37440826]
  6. Front Oncol. 2020 Oct 14;10:586603 [PMID: 33154948]
  7. Front Oncol. 2022 Feb 16;12:809277 [PMID: 35251979]
  8. Front Med (Lausanne). 2020 Oct 15;7:571154 [PMID: 33178717]
  9. Lancet Oncol. 2020 Dec;21(12):1620-1629 [PMID: 33271092]
  10. Cancer. 2000 May 15;88(10):2228-38 [PMID: 10820343]
  11. Int J Colorectal Dis. 2022 Jun;37(6):1411-1420 [PMID: 35595975]
  12. Br J Cancer. 2022 May;126(8):1178-1185 [PMID: 35043009]
  13. Chin J Cancer. 2017 Apr 28;36(1):41 [PMID: 28454595]
  14. Oncotarget. 2016 Apr 5;7(14):18269-79 [PMID: 26934317]
  15. Histopathology. 2021 Aug;79(2):168-175 [PMID: 33511676]
  16. Int J Colorectal Dis. 2018 Jan;33(1):19-22 [PMID: 29134274]
  17. Br J Surg. 2021 Jul 23;108(7):769-776 [PMID: 34244752]
  18. Ann Surg Oncol. 2018 Jun;25(6):1454-1455 [PMID: 29616422]
  19. J Clin Oncol. 2020 May 20;38(15):1702-1710 [PMID: 32167864]
  20. Am J Surg Pathol. 2015 Jan;39(1):109-15 [PMID: 25229767]
  21. Onco Targets Ther. 2015 Jan 22;8:233-40 [PMID: 25653544]
  22. Int J Colorectal Dis. 2020 Oct;35(10):1911-1919 [PMID: 32548720]
  23. J Cancer. 2018 Oct 10;9(21):3979-3985 [PMID: 30410602]
  24. J Surg Res. 2020 Jan;245:475-482 [PMID: 31446189]
  25. Ann Surg Oncol. 2023 Dec;30(13):8067-8073 [PMID: 37782414]
  26. J Pathol. 2023 Dec;261(4):401-412 [PMID: 37792663]
  27. J Natl Compr Canc Netw. 2022 Oct;20(10):1139-1167 [PMID: 36240850]
  28. Am J Clin Oncol. 2020 Feb;43(2):133-138 [PMID: 31764018]
  29. Sci Rep. 2020 Jan 9;10(1):89 [PMID: 31919408]
  30. Dis Colon Rectum. 2002 Jun;45(6):733-42; discussion 742-3 [PMID: 12072622]
  31. Int J Colorectal Dis. 2019 Aug;34(8):1375-1383 [PMID: 31201493]
  32. Am J Clin Pathol. 2010 Mar;133(3):388-94 [PMID: 20154277]
  33. BMC Cancer. 2015 Nov 06;15:859 [PMID: 26545360]
  34. Br J Cancer. 2023 Oct;129(6):917-924 [PMID: 37507544]
  35. J Rural Med. 2014;9(1):20-6 [PMID: 25648159]
  36. Ann Oncol. 2021 Oct;32(10):1267-1275 [PMID: 34293461]

Word Cloud

Created with Highcharts 10.0.0patientsTDIIIP = 0survivalstageCRCprognosisdepositcountcancer-specificCSSDFScancerchemotherapymortality1-2TDpoorimpacttumorcolorectalstagingoptimalvalueStagegroup≥3TD95%CI = 1recurrence024high-riskT4N21-2TD:HR = 095%CI = 0≥3TD:significantlyBackground:aimedevaluatedisease-freestratifiedTNexploreeffectMethod:determinedcut-offSEERdatabaseutilizingX-tileanalysisretrospectivelyanalyzedclinicopathologicaldata443FirstAffiliatedHospitalWenzhouMedicalUniversity20192020Chi-squareχ2testscomparedcategoricalvariablesKaplan-MeierassessedCoxregressionmodelevaluatedprognosticfactorsResults:2TDcutofflow-riskT1-T3N1facedhigherHR = 3445254-9465017risksHR = 1934095-3416vsno-TDshoweddifferenceChemotherapyreducedgroups347138-0870272077-0960043improverisk177058Conclusion:indicates≥3worseningyetremainsTD-positiveregardlessMoreoverinfluencechemotherapy'sbenefitPrognosticsignificancecountsbasedT/Nstatus:retrospectivecohortstudyAdjuvantColorectalPrognosisTumor

Similar Articles

Cited By